Study of 18F-Fluciclovine PET-MRI Scans to Monitor Treatment Response in Children and Young Adults With Low Grade Brain Tumors

What this Trial Is About

Researchers are evaluating the usefulness and safety of 18F-Fluciclovine Axumin in managing children and young adults with Low Grade Gliomas LGG, a type of brain tumor. This early phase 1 trial focuses on using 18F-Fluciclovine PET-MRI scans to observe tumor changes over time and compare these to standard MRI measurements. The study aims to improve understanding of tumor behavior during treatment in this young population. Participants will receive an injection of 18F-Fluciclovine before undergoing PET-MRI imaging. Scans will be performed before starting therapy for LGG, then again at 3 months and 1 year after treatment begins. The study will measure changes in the tumors uptake of 18F-Fluciclovine and compare them to MRI tumor size changes over the same periods. During the study, participants will have PET-MRI scans and standard MRI assessments at the scheduled times. Researchers will monitor tumor activity using standardized uptake values SUVmax and SUVpeak on the PET scans and tumor size on MRI. Safety of the 18F-Fluciclovine injection will also be tracked over 13 months. The total participation time is about one year with follow-up to evaluate these imaging outcomes and safety.

Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG